news
First animal model for Kaposi sarcoma developed
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
List view / Grid view
Drug Development
article
Women in Stem with Laura Figulla
Dr Laura Figulla is the CEO of mbiomics. Laura co-founded mbiomics which is dedicated to unlocking the true value of the microbiome by developing next-generation live biotherapeutics (LBPs). Throughout her career, Laura has combined her entrepreneurial spirit with her diverse academic background in business, economics, and medicine to build companies that…
article
Overcoming the complexity of free energy perturbation calculations
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
article
Developing the next generation of antibody drug conjugates
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
article
Women in Stem with Lidia Pieri
Lidia Pieri earned a Master’s degree with honours in high energy physics at CERN, a PhD in theoretical astroparticle physics from Rome-3 (Italy) and an Executive MBA in Business Innovation with honours from the MIB school in Trieste. During the academic period she gained international exposure and recognition working as…
news
Drug-loaded 3D printed films could revolutionise liver cancer treatment
The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
article
Pioneering the advancement of pre-targeted radioimmunotherapies
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
news
FOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
news
Investigating new treatments for polycystic kidney disease
Organoid models enabled the researchers to study the effectiveness of eukaryotic ribosomal selective glycoside drugs on PKD cyst formation.
news
Exploring the effects of IFNβ in neuroHIV infection
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
news
New treatment for metabolic dysfunction-associated steatohepatitis
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
news
New AI model could help to overcome antibiotic resistance
Six molecules that had potent antibacterial effect against one of the world’s most dangerous antibiotic-resistant bacteria were generated.
news
FGF2 and SOX17 enable more efficient stem cell differentiation
The discovery of two proteins that effectively mature hiPSCs into endothelial cells may have a range of research and clinical benefits.
news
New strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
news
The mechanism of PARP inhibitor action is identified
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
